News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
545,864 Results
Type
Article (49157)
Company Profile (247)
Press Release (496442)
Multimedia
Podcasts (96)
Webinars (19)
Section
Business (151241)
Career Advice (1541)
Deals (25055)
Drug Delivery (111)
Drug Development (66529)
Employer Resources (161)
FDA (10418)
Job Trends (11299)
News (253554)
Policy (20263)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2419)
Academic (2)
Accelerated approval (25)
Adcomms (27)
Allergies (89)
Alliances (38237)
ALS (147)
Alzheimer's disease (1459)
Antibody-drug conjugate (ADC) (323)
Approvals (10651)
Artificial intelligence (440)
Autoimmune disease (144)
Automation (31)
Bankruptcy (183)
Best Places to Work (8987)
BIOSECURE Act (17)
Biosimilars (141)
Biotechnology (164)
Bladder cancer (136)
Brain cancer (52)
Breast cancer (566)
Cancer (4508)
Cardiovascular disease (320)
Career advice (1318)
Career pathing (39)
CAR-T (301)
CDC (36)
Celiac Disease (2)
Cell therapy (819)
Cervical cancer (28)
Clinical research (55658)
Collaboration (1520)
Company closure (3)
Compensation (739)
Complete response letters (40)
COVID-19 (2198)
CRISPR (94)
C-suite (777)
Cystic fibrosis (122)
Data (5479)
Decentralized trials (1)
Denatured (36)
Depression (98)
Diabetes (374)
Diagnostics (5325)
Digital health (26)
Diversity (11)
Diversity, equity & inclusion (43)
Drug discovery (237)
Drug pricing (96)
Drug shortages (11)
Duchenne muscular dystrophy (194)
Earnings (59083)
Editorial (42)
Employer branding (24)
Employer resources (142)
Events (89463)
Executive appointments (874)
FDA (12789)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (19)
Funding (1242)
Gene editing (194)
Generative AI (47)
Gene therapy (572)
GLP-1 (690)
Government (2884)
Grass and pollen (3)
Guidances (300)
Healthcare (13276)
HIV (48)
Huntington's disease (39)
IgA nephropathy (64)
Immunology and inflammation (201)
Immuno-oncology (52)
Indications (87)
Infectious disease (2409)
Inflammatory bowel disease (171)
Inflation Reduction Act (10)
Influenza (92)
Intellectual property (176)
Interviews (245)
IPO (12151)
IRA (27)
Job creations (2635)
Job search strategy (1143)
JPM (54)
Kidney cancer (16)
Labor market (82)
Layoffs (437)
Leadership (26)
Legal (4277)
Liver cancer (83)
Longevity (13)
Lung cancer (667)
Lymphoma (379)
Machine learning (37)
Management (50)
Manufacturing (637)
MASH (121)
Medical device (7884)
Medtech (7921)
Mergers & acquisitions (13782)
Metabolic disorders (896)
Multiple sclerosis (144)
NASH (15)
Neurodegenerative disease (279)
Neuropsychiatric disorders (55)
Neuroscience (2487)
Neurotech (1)
NextGen: Class of 2026 (4565)
Non-profit (3357)
Now hiring (65)
Obesity (389)
Opinion (227)
Ovarian cancer (152)
Pain (145)
Pancreatic cancer (195)
Parkinson's disease (249)
Partnered (31)
Patents (325)
Patient recruitment (364)
Peanut (36)
People (50003)
Pharmaceutical (49)
Pharmacy benefit managers (7)
Phase 1 (18264)
Phase 2 (24645)
Phase 3 (18111)
Pipeline (4306)
Policy (187)
Postmarket research (1820)
Preclinical (8632)
Press Release (72)
Prostate cancer (204)
Psychedelics (39)
Radiopharmaceuticals (239)
Rare diseases (703)
Real estate (4661)
Recruiting (64)
Regulatory (16459)
Reports (58)
Research institute (2304)
Resumes & cover letters (231)
Rett syndrome (25)
RNA editing (15)
RSV (63)
Schizophrenia (125)
Series A (207)
Series B (147)
Service/supplier (9)
Sickle cell disease (104)
Special edition (17)
Spinal muscular atrophy (145)
Sponsored (36)
Startups (3117)
State (2)
Stomach cancer (17)
Supply chain (67)
Tariffs (41)
The Weekly (59)
Vaccines (753)
Venture capital (80)
Weight loss (229)
Women's health (58)
Worklife (20)
Date
Today (40)
Last 7 days (473)
Last 30 days (1650)
Last 365 days (24535)
2026 (2353)
2025 (24808)
2024 (29088)
2023 (33015)
2022 (41735)
2021 (44903)
2020 (41350)
2019 (33809)
2018 (25560)
2017 (25438)
2016 (24443)
2015 (29527)
2014 (23364)
2013 (19967)
2012 (19712)
2011 (20101)
2010 (19000)
Location
Africa (658)
Alabama (48)
Alaska (6)
Arizona (205)
Arkansas (7)
Asia (31940)
Australia (5854)
California (9116)
Canada (2611)
China (898)
Colorado (351)
Connecticut (373)
Delaware (303)
Europe (74637)
Florida (1235)
Georgia (283)
Hawaii (3)
Idaho (43)
Illinois (572)
India (52)
Indiana (395)
Iowa (20)
Japan (372)
Kansas (78)
Kentucky (30)
Louisiana (19)
Maine (63)
Maryland (1020)
Massachusetts (6887)
Michigan (277)
Minnesota (409)
Mississippi (5)
Missouri (97)
Montana (26)
Nebraska (25)
Nevada (103)
New Hampshire (41)
New Jersey (2545)
New Mexico (28)
New York (2481)
North Carolina (1195)
North Dakota (9)
Northern California (4486)
Ohio (263)
Oklahoma (12)
Oregon (40)
Pennsylvania (1679)
Puerto Rico (13)
Rhode Island (39)
South America (851)
South Carolina (33)
Southern California (3506)
Tennessee (120)
Texas (1425)
United States (32092)
Utah (275)
Vermont (1)
Virginia (173)
Washington D.C. (66)
Washington State (793)
West Virginia (3)
Wisconsin (112)
Wyoming (1)
545,864 Results for "cel sci corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CEL-SCI Reports Fiscal 2025 Results
December 29, 2025
·
7 min read
Press Releases
CEL-SCI Announces Proposed Public Offering
August 28, 2025
·
4 min read
Press Releases
CEL-SCI Announces Closing of $10 Million Public Offering
September 1, 2025
·
3 min read
Press Releases
CEL-SCI Announces Pricing of $10 Million Public Offering
August 28, 2025
·
3 min read
Press Releases
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
August 15, 2025
·
7 min read
Press Releases
CEL-SCI Announces Combination of Common Stock
May 20, 2025
·
4 min read
Business
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments.
May 16, 2024
·
7 min read
Press Releases
CEL-SCI Announces Proposed Public Offering - May 21, 2025
May 22, 2025
·
4 min read
Press Releases
CEL-SCI Announces Pricing of Public Offering - May 21, 2025
May 22, 2025
·
4 min read
Press Releases
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
May 15, 2025
·
5 min read
1 of 54,587
Next
